

(THE "COMPANY" AND TOGETHER WITH ITS SUBSIDIARIES, THE "GROUP") (Incorporated in the Republic of Singapore under Registration Number 201506891C)

Unaudited Condensed Interim Financial Statements For the six months ended 30 November 2022

Contents

	Page
Condensed interim consolidated statement of profit or loss and other comprehensive income	2-3
Condensed interim statements of financial position	4-5
Condensed interim statements of changes in equity	6-7
Condensed interim consolidated statement of cash flows	8-9
Notes to the condensed interim consolidated financial statements	10-24
Other information required by Listing Rule Appendix 7C	25-33

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms. Charmian Lim (telephone no.: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.



Condensed interim consolidated statement of profit or loss and other comprehensive income For the six months ended 30 November 2022

	_		The Group	
		Half Year Ended		
	Note	30 Nov 2022 \$'000 (Unaudited)	30 Nov 2021 \$'000 (Unaudited)	Change %
Revenue	4	16,945	7,994	>100
Other income		139	86	61.6
Subcontractor costs and direct costs		(12,858)	(5,407)	>100
Employee benefits expenses – Project		(529)	(67)	>100
Employee benefits expenses – Administrative		(1,943)	(1,806)	7.6
Depreciation and amortisation expenses		(2,948)	(2,481)	18.8
Legal and professional expenses		(2,050)	(2,724)	(24.7)
Other expenses		(1,540)	(682)	>100
Finance costs		(50)	(77)	(35.1)
Share of profit from equity-accounted for associate	-	27		N.M
Loss before tax	6	(4,807)	(5,164)	(6.9)
Income tax credit	7	318	161	97.5
Loss for the period from continuing operations, net of tax		(4,489)	(5,003)	(10.3)
Discontinued operations Loss for the period from discontinued operations, net of tax	6.3		(690)	N.M
Loss for the period	-	(4,489)	(5,693)	(21.1)
Other comprehensive (loss)/income: Items that are or may be reclassified subsequently to profit or loss				
Currency translation differences arising on consolidation	-	(489)	154	N.M
Other comprehensive (loss)/income for the period, net of tax	-	(489)	154	N.M
Total comprehensive loss for the period		(4,978)	(5,539)	(10.1)



Condensed interim consolidated statement of profit or loss and other comprehensive income (Continued) For the six months ended 30 November 2022

			The Crew	
	-	The Group		
			alf Year Ended	
		30 Nov 2022	30 Nov 2021	Change
	Note	\$'000	\$'000	%
		(Unaudited)	(Unaudited)	
Loss for the period attributable to:				
Equity holders of the Company				
 continuing operations 		(4,294)	(4,601)	(6.7)
- discontinued operations		-	(690)	N.M
Non-controlling interests				
- continuing operations		(195)	(402)	(51.5)
		(4,489)	(5,693)	(21.1)
Total comprehensive loss for the period attributable to:				
Equity holders of the Company		(4,530)	(5,249)	(13.7)
Non-controlling interests		(448)	(290)	N.M
		(4,978)	(5,539)	(10.1)
Loss per share for loss attributable to equity holders of the Company				
From continuing and discontinued operations				
Basic and diluted (cents per share)	6.4	(0.49)	(0.65)	(24.6)
From continuing operations				
Basic and diluted (cents per share)	6.4	(0.49)	(0.56)	(12.5)
From discontinued operations				
Basic and diluted (cents per share)			(0.09)	N.M

N.M – Not Meaningful



Condensed interim statements of financial position As at 30 November 2022

		The C	Group	The Co	ompany
		As	at	As	at
	3	30 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022
	Note	\$'000	\$'000	\$'000	\$'000
ASSETS					
Non-current assets					
Property, plant and equipment	10	2,284	2,652	1,318	1,535
Intangible assets	11	40,156	42,373	210	4
Investment in subsidiaries		-	-	35,267	35,267
Investment in an associate	12	13,784	13,757	14,670	14,670
Financial asset at fair value through profit					
or loss	9	5,516	5,506	5,516	5,506
Amount due from a subsidiary	13	-	-	852	883
Deferred tax assets	_	62	67		
Total non-current assets	_	61,802	64,355	57,833	57,865
Current assets					
Contract assets		1,432	2,496	_	_
Amounts due from subsidiaries		-	_	1,777	614
Trade and other receivables		15,602	3,941	325	323
Cash and cash equivalents		15,081	4,939	11,651	4,156
Total current assets	_	32,115	11,376	13,753	5,093
Total assets	_	93,917	75,731	71,586	62,958
	=				
EQUITY AND LIABILITIES					
Equity attributable to owners of the					
Company			· · · · -		
Share capital	14	101,991	90,225	101,991	90,225
Other reserves		(193)	43	-	-
Accumulated losses	_	(37,286)	(32,992)	(32,710)	(29,374)
Equity attributable to equity holders of					
the Company		64,512	57,276	69,281	60,851
Non-controlling interests	_	10,635	11,083		
Total equity		75,147	68,359	69,281	60,851
	_				



Condensed interim statements of financial position (Continued) As at 30 November 2022

			Group	The Company As at		
	3	0 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022	
	Note	\$'000	\$'000	\$'000	\$'000	
Non-current liabilities						
Lease liabilities		827	1,155	692	963	
Employee benefit liabilities		262	268	-	-	
Deferred tax liabilities	_	3,436	3,866		_	
Total non-current liabilities		4,525	5,289	692	963	
Current liabilities						
Contract liabilities		14	15	-	-	
Trade and other payables		13,446	1,320	887	502	
Amounts due to subsidiaries		-	-	36	-	
Lease liabilities	_	785	748	690	642	
Total current liabilities	_	14,245	2,083	1,613	1,144	
Total liabilities		18,770	7,372	2,305	2,107	
Total equity and liabilities	_	93,917	75,731	71,586	62,958	



Condensed interim statement of changes in equity For the six months ended 30 November 2022

	Attributa	New				
	Share capital (Note 14)	Other reserves	Accumulated losses	Total	Non- controlling interests	Total equity
	\$'000	\$ ' 000	\$'000	\$ ' 000	\$'000	\$'000
(Unaudited) The Group						
Balance at 1.6.2022	90,225	43	(32,992)	57,276	11,083	68,359
Loss for the period Other comprehensive loss:	-	-	(4,294)	(4,294)	(195)	(4,489))
Currency translation differences arising on consolidation	-	(236)	_	(236)	(253)	(489)
Total comprehensive loss for the period	-	(236)	(4,294)	(4,530)	(448)	(4,978)
Issue of ordinary shares	12,173	-	-	12,173	_	12,173
Shares issue expenses	(407)	_	-	(407)	_	(407)
Balance at 30.11.2022	101,991	(193)	(37,286)	64,512	10,635	75,147
The Group						
Balance at 1.6.2021	63,003	(8,388)	(13,983)	40,632	11,853	52,485
Loss for the period Other comprehensive loss:	-	-	(5,291)	(5,291)	(402)	(5,693)
Currency translation differences arising on consolidation	_	42	-	42	112	154
Total comprehensive loss for the period	-	42	(5,291)	(5,249)	(290)	(5,539)
Issue of ordinary shares	26,325	-	-	26,325	_	26,325
Shares issue expenses	(853)	-	-	(853)	-	(853)
Issue of ordinary shares (acquisition of a subsidiary)	1,759	(7)	-	1,752	776	2,528
Balance at 30.11.2021	90,234	(8,353)	(19,274)	62,607	12,339	74,946



Condensed interim statement of changes in equity (Continued) For the six months ended 30 November 2022

	Share capital (Note 14) \$'000	Accumulated losses \$'000	Total equity \$'000
(Unaudited) The Company			
Balance at 1.6.2022	90,225	(29,374)	60,851
Loss and total comprehensive loss for the period	_	(3,336)	(3,336)
Issue of ordinary shares	12,173	-	12,173
Shares issue expenses	(407)	_	(407)
Balance at 30.11.2022	101,991	(32,710)	69,281
The Company			
Balance at 1.6.2021	63,003	(22,866)	40,137
Loss and total comprehensive loss for the period	-	(4,269)	(4,269)
Issue of ordinary shares	26,325	-	26,325
Shares issue expenses	(853)	-	(853)
Issue of ordinary shares (acquisition of a subsidiary)	1,759	-	1,759
Balance at 30.11.2021	90,234	(27,135)	63,099



Condensed interim consolidated statement of cash flows

For the six months ended 30 November 2022

	The Group	
	2022	2021
	\$'000	\$'000
Cash flows from operating activities		
Loss before tax from continuing operations	(4,807)	(5,164)
Loss before tax from discontinued operations	-	(690)
Adjustments for:		
Depreciation and amortisation expenses	2,948	2,654
Gain on disposal of property, plant and equipment	-	(1)
(Gain)/loss on foreign exchange	(412)	7
Defined benefits plans	_	(4)
Reversal of retirement benefit obligation	(6)	_
Interest expenses	50	151
Interest income	-	(1)
Share of profit from equity-accounted associate	(27)	-
Operating cash flows before movements in working capital	(2,254)	(3,048)
Changes in working capital:		
Inventories	-	(52)
Contract assets	1,064	2,524
Trade and other receivables	(11,661)	(7,507)
Contract liabilities	(1)	-
Trade and other payables	12,126	(6,268)
Cash used in operations	(726)	(14,351)
Interest received	_	1
Income tax paid	(107)	(226)
Net cash used in operating activities	(833)	(14,576)



Condensed interim consolidated statement of cash flows (Continued)

For the six months ended 30 November 2022

	The Group	
	2022	2021
	\$'000	\$'000
Cash flows from investing activities		
Purchase of property, plant and equipment (Note 10)	(117)	(35)
Purchase of intangible assets	(207)	_
Acquisition of a subsidiary, net of cash acquired	-	(877)
Purchase of financial assets at fair value through profit or loss	_	(10,832)
Net cash used in investing activities	(324)	(11,744)
Cash flows from financing activities		
Proceeds from issuance of ordinary shares	12,173	26,325
Shares issue expenses	(407)	(853)
Proceeds from borrowings	-	1,079
Repayment of shareholder/ former shareholder's loan	-	(279)
Repayment of lease liabilities	(383)	(527)
Repayment of borrowings	-	(470)
Interest paid	(50)	(76)
Net cash generated from financing activities	11,333	25,199
Net increase/(decrease) in cash and cash equivalents	10,176	(1,121)
Cash and cash equivalents at beginning of period	4,939	12,556
Effect of exchange rate fluctuation on cash and cash equivalents	(34)	_
Cash and cash equivalents at end of period	15,081	11,435
Cash and cash equivalent comprised of the following:		
Cash and bank balances	15,081	11,535
Less: Pledged bank deposits	_	(100)
Cash and cash equivalent	15,081	11,435



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

1 Corporate information

The Company

TOTM Technologies Limited (formerly known as Yinda Infocomm Limited) (the "**Company**") (Co. Reg. No. 201506891C) is a limited liability company incorporated and domiciled in Singapore and is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").

These condensed interim consolidated financial statements are as at and for the six months ended 30 November 2022 comprised the Company and subsidiaries (collectively, the "**Group**"). The principal activity of the Company is that of investment holding.

The principal activities of the significant subsidiaries are:

- a) Providing information technology consulting, computer and computer facility management services.
- b) Providing information technology and computer services (development and sale of identity management technologies).
- c) Investment holding.

2 Basis of preparation

The condensed interim financial statements for the six months ended 30 November 2022 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("SFRS(I)") 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of consolidated financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 May 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar ("**SGD**" or "**\$**"), which is the Company's functional currency. All financial information has been rounded to the nearest thousand, unless otherwise stated.

2.1 New and amended standards adopted by the Group

The condensed interim financial statements have been prepared based on accounting policies and method of computation consistent with those adopted in the most recent audited financial statements of the Group for the financial year ended 31 May 2022. The Group has adopted new and revised SFRS(I) and interpretations of SFRS(I) applicable to the Group which are effective for the financial year beginning 1 June 2022. These are not expected to have a material impact on the Group's condensed interim financial statements.



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

2.2 Use of judgements and estimates

In preparing the condensed interim financial statement, management has made judgements, estimates and assumption that affect the application of accounting policies and the reported amount of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to consolidated financial statements as at and for the year ended 31 May 2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

There is no critical judgement made in applying accounting applying accounting policies that have the most significant effect on the amount recognised in the financial statement, or have a significant risk of resulting in a material adjustments to the carrying amounts of assets and liabilities within the next financial period, other than the key sources of estimation uncertainty below.

2.3 Key sources of estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that has a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Impairment of non-financial assets (other than goodwill and other indefinite-life intangible assets)

At the end of each reporting period, the Group and the Company assess whether there are any indications of impairment for all non-financial assets. If any such indication exists, the Group and the Company estimate the recoverable amount of that asset. An impairment loss exists when the carrying value of an asset exceeds its recoverable amount, which is the higher of its fair value less costs to sell and its value in use.

Where value in use calculations are undertaken, management is required to estimate the expected future cash flows from the asset or cash-generating unit and a suitable discount rate in order to determine the present value of the cash flows.

Impairment assessment of goodwill

Management performs an annual impairment assessment of goodwill or more frequently if there are indications that goodwill might be impaired. Valuation model based on discounted cash flow analysis of the cash-generating unit is used by management to determine the value in use for the purposes of the impairment assessment.

Forecasting and discounting future cash flows for the impairment assessment involves an element of judgement and requires management to make certain assumptions and apply estimates.



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

2.3 Key sources of estimation uncertainty (Continued)

Allowance for expected credit losses of trade receivables and contract assets

The Group applies the simplified approach by using a provision matrix to measure the lifetime expected credit loss allowance for trade receivables and contract assets. Trade receivables and contract assets that shared the same credit risk characteristics and days past due are grouped together in measuring the expected credit losses.

The provision matrix is initially based on the Group's historical observed default rates. The Group will assess the historical credit loss experience by considering current and forecast economic conditions with consideration on the impact of COVID-19 pandemic and how these conditions will affect the Group's ECL assessment. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future.

Impairment of investment in subsidiaries

At the end of each reporting period, the Company assesses whether there are any indications of impairment for investment in subsidiaries. The Company also assesses whether there is any indication that an impairment loss recognised in prior periods for investment in subsidiaries may no longer exist or may have decreased.

If any such indication exists, the Company estimates the recoverable amount of that asset. An impairment loss exists when the carrying value of an asset exceeds its recoverable amount, which is the higher of its fair value less costs to sell and its value in use. An impairment loss recognised in prior periods shall be reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised.

Where value in use calculations are undertaken, management is required to estimate the expected future cash flows from the asset or cash-generating unit and a suitable discount rate in order to determine the present value of the cash flows. The value in use calculation involves significant judgement in the forecast projection of sales and operating cash flows for the next five years including the consideration on the implications of the COVID-19 pandemic.

3 Seasonal operations

The Group's business are not affected significantly by seasonal or cyclical factors during the financial period.

4 Segment and revenue information

The Biometrics business is presented based on geographical segments, mainly Singapore, Indonesia, India and United States of America. As at 31 May 2022, the entity incorporated in United States in respect of the Biometrics business has yet to commence operation. Management monitors the operating results of its business units separately for making decisions about allocation of resources and assessment of performances of each segment. These operating resources and assessing performance of the operating resources and assessing performance of the operating segments.

The Company disposed its 100% equity interest in subsidiaries, Yinda Technology Singapore Pte. Ltd ("**YTS**") and Yinda Technologies (Thailand) Co., Ltd. ("**YTT**") during the financial year ended 31 May 2022. Accordingly, information about the profit or loss, assets and liabilities relating to YTS and YTT were presented under "Discontinued Operations". In addition, the Group has re-represented the information about the profit or loss, assets and liabilities relating to YTS and YTT as "Discontinued Operations" for the period ended 30 November 2021.



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

4.1 Reportable segment

The segment information provided to management for the reportable segments are as follows:

	Singapore	Indonesia	India	USA	Adjustments and eliminations	The Group
From 1 June 2022 to 30 November 2022	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Total segment revenue Intersegment revenue	14,388 (50)	3,109 (502)	556 (556)	_	(1,108) 1,108	16,945 _
Total revenue from external parties	14,338	2,607	-	_	-	16,945
Operating (loss)/profit	(3,230)	486	72	(2)	(2,110)	(4,784)
Interest income Finance costs	13 (59)	9 (10)	(3)	-	(22) 22	_ (50)
(Loss)/profit before tax Share of profit from equity- accounted for associate Income tax credit Loss for the period	(3,276)	485	69	(2)	(2,110)	(4,834) 27 318 (4,489)
Other significant non-cash items Depreciation and amortisation expenses	599	207	17	_	2,125	2,948
Assets Segment assets	89,725	8,187	195	14	(4,204)	93,917
Segment assets include Additions to non-current assets	333	19	80	_	_	432
Liabilities Segment liabilities	19,127	1,422	168	48	(1,995)	18,770



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

4.1 Reportable segment (Continued)

The segment information provided to management for the reportable segments are as follows:

	Continuing o	perations	Discontinued operations				
	Singapore	Indonesia	Singapore	Thailand	Adjustments	The Group	
From 1 king 2021 to 20	<i>.</i>	<i>.</i>	61000	<i>.</i>	and eliminations	41000	
From 1 June 2021 to 30 November 2021	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	
Total segment revenue	4,918	3,191	1,139	985	(115)	10,118	
Intersegment revenue	-	(115)	-	-	115		
Total revenue from external							
parties	4,918	3,076	1,139	985	-	10,118	
Operating (loss)/profit	(4,187)	1,136	(156)	(446)	(2,050)	(5,703)	
Interest income	61	_	_	_	(60)	1	
Finance costs	(135)	(2)	(64)	(11)	60	(152)	
(Loss)/profit before tax Income tax credit	(4,261)	1,134	(220)	(457)	(2,050)	(5,854) 161	
Loss for the period					-	(5,693)	
Other significant non-cash items Depreciation and amortisation expenses	313	117	151	10	2,063	2,654	
Segment assets	78,306	8,382	3,523	3,472	(2,489)	91,194	
Segment assets include							
Additions to non-current assets	3,468	10	2	17		3,497	
Liabilities							
Segment liabilities	12,627	828	6,760	2,338	(6,305)	16,248	



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

4.2 Disaggregation of revenue

	The G	The Group		
	6 months ended	6 months ended		
	30 Nov 2022	30 Nov 2021		
	\$'000	\$'000		
Primary geographical market				
Singapore	14,338	4,918		
Indonesia	2,607	3,076		
	16,945	7,994		
Major service lines				
Biometrics business	16,945	7,994		
Timing of revenue recognition				
Over time	2,607	3,076		
At a point in time	14,338	4,918		
	16,945	7,994		

5 Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group and the Company as at 30 November 2022 and 31 May 2022:

	The Group		The Company	
	30 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022
	\$'000	\$'000	\$'000	\$'000
Financial assets Financial assets at fair value through				
profit or loss	5,516	5,506	5,516	5,506
Financial assets at amortised cost	29,011	7,388	14,461	5,894
	34,527	12,894	19,977	11,400
Financial liabilities				
Financial liabilities at amortised cost	14,886	3,172	2,305	2,105



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

6 Loss before taxation

6.1 Significant items

	The Group		
	6 months ended 30 Nov 2022 \$'000	6 months ended 30 Nov 2021 \$'000	
Income includes:			
Government grants	119	85	
Others	7		
Expenses includes:			
Amortisation of intangible assets (Note 11)	2,424	2,085	
Depreciation of property, plant and equipment	524	396	
Foreign exchange (gain)/loss, net	(13)	60	
Operating lease expense - short-term leases	44	8	

6.2 Related party transactions

In addition to the related party transactions disclosed elsewhere in the interim financial statements, the following significant transactions between the Group and related parties took place during the financial period under review:

		The G	The Group		
		6 months ended 30 Nov 2022 \$'000	6 months ended 30 Nov 2021 \$'000		
a)	Associate company				
	Service fee charged	1,981	640		
b)	Key management personnel				
	Salaries and remuneration	499	503		
	Employer's contribution to defined contribution plans	17	17		
	Fees and other benefits	137	5		
		653	525		
	Comprise amounts paid to:				
	Directors of the Company	584	463		
	Other key management personnel	69	62		
		653	525		



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

6.3 Discontinued operations

During the second half of financial year 31 May 2022, the Company disposed its equity interest in its wholly owned subsidiaries, YTS and YTT. The financial performance of YTS and YTT in financial year 2022 were presented in a single amount separately on the consolidated statement of profit or loss and other comprehensive income as "Discontinued Operations". In addition, the Group has re-presented the financial performance of YTS and YTT as "Discontinued Operations" for the six months ended 30 November 2021.

	6 months ended
	30 Nov 2021
	\$'000
Revenue	2,124
Other income	133
Changes in inventories, material	()
consumed and subcontractor costs	(404)
Employee herefite evenences. Dreiget	
Employee benefits expenses – Project related	
related	(1,577)
Employee benefits expenses –	
Administrative	(405)
Auministrative	(405)
Depreciation and amortisation	
expenses	(173)
	(- <i>r</i>
Legal and professional expenses	(59)
Other expenses	(254)
Finance costs	(75)
Loss before tax	(690)
Income tax expense	_
Loss for the period from discontinued	
operations, net of tax	(690)
	(030)
Other comprehensive loss:	
Items that are or may be reclassified	
subsequently to profit or loss	
Currency translation differences arising	
on consolidation	(60)
Total comprehensive loss for the period	(750)



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

6.4 Loss Per Share

Basic loss per share is calculated based on the Group's loss for the period attributable to equity holders of the Company divided by the weighted average number of ordinary shares outstanding.

	The	Group	
	6 months ended 30 Nov 2022 \$'000	6 months ended 30 Nov 2021 \$'000	
Loss for the period attributable to equity holders of the Company (\$'000)	(4,294)	(5,291)	
Weighted average number of ordinary shares outstanding for basic and diluted loss per share ('000)	874,082	819,115	
Basic and diluted loss per share (cents per share)	(0.49)	(0.65)	

7 Taxation

The Group calculates the period income tax expense/(credit) using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense/(credit) in the condensed interim consolidated statement of profit or loss and other comprehensive income are:

	The	The Group			
	6 months ended 30 Nov 2022 \$'000	6 months ended 30 Nov 2021 \$'000			
ent tax: rent year	112	256			
l tax: year	(430)	(417)			
	(318)	(161)			



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

8 Net asset value

	The Group As at		The Company As at	
	30 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022
Net assets (\$'000)	64,512	57,276	69,281	60,851
Number of ordinary shares used in calculating net asset value per ordinary share ('000)	953,704	849,304	953,704	849,304
Net asset value per ordinary share attributable to owners of the Company (cents)	6.76	6.74	7.26	7.16

9 Financial assets at fair value through profit or loss ("FVTPL")

	The Group		The Cor	npany
	30 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022
	\$'000	\$'000	\$'000	\$'000
Investments measured at FVTPL				
Unquoted investment in Indonesia Convertible bond investment in	369	369	369	369
Indonesia	5,147	5,137	5,147	5,137
	5,516	5,506	5,516	5,506

Unquoted investment in Indonesia

On 10 May 2021, the Group has entered into a convertible loan arrangement with PT Pattra Aksa Jaya ("**PAJ**") whereby the Group agreed to subscribe for a convertible loan with principal amount of approximately \$370,000 at 2.75% interest rate. The convertible loan has a maturity date of 3 months from the agreement date. In accordance with the convertible loan arrangement, the Group may elect to require PAJ to automatically issue 261 ordinary shares to the Group on the maturity date by giving PAJ at least 7 days prior notice in writing of such election. The Company has exercised its conversion right on 5 August 2021 to convert the total principal amount of the convertible loan to 261 shares in PAJ, representing approximately 8% of the enlarged issued shares capital of PAJ. The PAJ shares has been allotted and issued to the Company and the conversion was completed on 19 August 2021.

The Group has classified the investment as financial assets at fair value through profit or loss at initial recognition and at the end of the reporting period. The Group has determined the fair value of the investment based on the valuation performed by an external professional valuer using the discounted cash flow method. The key inputs to the discounted cash flow method mainly include the discount rate, time to maturity, coupon rate and probability of conversion. Management considered the appropriateness of the valuation technique and assumptions applied by the external valuer. The fair value measurement is categorised in Level 3 of the fair value hierarchy.



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

9 Financial assets at fair value through profit or loss ("FVTPL") (Continued)

Convertible bond investment in Indonesia

On 13 December 2021, the Group has entered into a convertible loan arrangement with PT. Cakrawala Data Integrasi ("**CDI**") whereby the Group agreed to subscribe for a convertible loan with principal amount of U\$3,750,000 (equivalent to approximately \$5,122,000 at 7.0% interest rate. The convertible loan has a maturity date of 2.5 years from the agreement date.

The Group has classified the investment as financial assets at fair value through profit or loss at initial recognition and at the end of the reporting period. The Group has determined the fair value of the investment based on the valuation performed by an external professional valuer by using Binomial model. The key inputs to the Binomial model is the market value of the share and conversion price. Management considered the appropriateness of the valuation technique and assumptions applied by the external valuer. The fair value measurement is categorised in Level 3 of the fair value hierarchy.

9.1 Fair value measurement

The Group classifies financial assets measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the input for assets which are not based on observable market data (unobservable inputs) (Level 3).

The following table presented the assets measured at fair value:

	The Gr	The Group		mpany	
	30 Nov 2022	30 Nov 2022 31 May 2022		31 May 2022	
	\$'000	\$'000	\$'000	\$'000	
Financial assets					
Level 3	5,516	5,506	5,516	5,506	

10 Property, plant and equipment

During the six months ended 30 November 2022, the Group acquired assets amounting to \$117,000 (30 Nov 2021: \$35,000) and disposed assets amounting to \$ Nil (30 Nov 2021: \$Nil).



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

11 Intangible assets

	Goodwill \$'000	Software \$'000	Technology \$'000	Customer relationships \$'000	Total \$'000
The Group					
Cost					
At 1.6.2022	20,651	15	17,085	9,936	47,687
Additions	-	207	-	_	207
Currency translation differences	_	-	_	-	_
At 30.11.2022	20,651	222	17,085	9,936	47,894
Accumulated amortisation					
At 1.6.2022	-	2	3,817	1,495	5,314
Amortisation charge	-	2	1,781	641	2,424
Currency translation differences	_	-	-	_	_
At 30.11.2022		4	5,598	2,136	7,738
Net carrying value					
At 30.11.2022	20,651	218	11,487	7,800	40,156



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

11 Intangible assets (Continued)

	Goodwill \$'000	Software \$'000	Technology \$'000	Customer relationships \$'000	Total \$'000
The Group					
Cost					
At 1.6.2021	20,255	2	13,709	18,940	52,906
Acquisition of a subsidiary	396	_	3,376	_	3,772
Additions	_	13	_	_	13
Disposal of subsidiaries	-	-	-	(8,986)	(8,986)
Currency translation differences	-	-	-	(18)	(18)
At 31 May 2022	20,651	15	17,085	9,936	47,687
Accumulated amortisation					
At 1.6.2021	-	-	481	9,217	9,698
Amortisation charge	-	2	3,336	1,282	4,620
Disposal of subsidiaries Currency translation differences				(8,986)	(8,986)
currency translation unreferices		_	_	(18)	(18)
At 31 May 2022	_	2	3,817	1,495	5,314
Net carrying value					
At 31 May 2022	20,651	13	13,268	8,441	42,373

Composition of intangible assets

- (i) Goodwill arising on the acquisition of InterBIO group and GenesisPro Pte Ltd.;
- (ii) Software refers to the Windows applications relating to identity management and other finance related software purchased by InterBIO group;
- (iii) Technology refers to in-house developed software technology that has been copyrighted and know-how (i.e. experience in building and maintaining the Indonesia National ID Database) in relation to Biometrics business;
- (iv) The additions of Technology during the financial year ended 31 May 2022 includes the front-end application for KYC admin console purchased during the acquisition of GenesisPro Pte Ltd; and
- (v) Customer relationships refer to the economic benefits that are expected to be derived from non-contractual existing and recurring relationships of the following cash-generating units and their existing customers:
 - i) YTS and disposed during the year
 - ii) YTT and disposed during the year
 - iii) InterBIO group



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2022

12 Investment in an associate

On 22 October 2021, the Company has completed the US\$8.0 million (approximate \$10.8 million) investment by way of subscription of new shares in the capital of TECH5 as well as exercise its rights to convert the US\$2.5 million (approximate \$3.8 million) convertible loan into new shares in TECH5. With the completion of these transactions, the Company's Chief Executive Officer and Executive Director, Mr Pierre Prunier, has been appointed as a director on the board of TECH5 and the Group holds 16.27% of TECH5 as at the date of this report. The management assessed that the Company demonstrated significant influence based on requirement of SFRS(I) 1-28 Investments in Associates and Joint Ventures ("SFRS(I) 1-28").

13 Amount due from a subsidiary

	The Company		
	30 Nov 2022 31 May		
	\$'000		
Amount due from a subsidiary	852	883	

The amount due from a subsidiary presents the convertible loan extended by the Company to GenesisPro, which can be convertible by the Company into new shares in the share capital of GenesisPro, at interest of 3% per annum.

Subject to the conversion right of the Company, GenesisPro shall repay the outstanding principal amount of the convertible loan, together with the outstanding accrued interest, without demand and without any deduction or withholding, within two years from the utilisation date of the convertible loan.

14 Share Capital

	The Group and the Company Number of shares			
	30 Nov 2022	31 May 2022	30 Nov 2022	31 May 2022
	'000	'000	\$'000	\$'000
Issued and fully paid ordinary shares				
At beginning of financial period	849,304	647,266	90,225	63,003
Issue of ordinary shares	104,400	202,038	12,173	28,084
Shares issue expenses		-	(407)	(862)
At end of financial period	953,704	849,304	101,991	90,225



Notes to the condensed interim consolidated financial statements For the six months ended 30 November 2021

14 Share Capital (Continued)

All issued shares are fully paid ordinary shares with no par value.

The Company allotted and issued 33,400,000 and 71,000,000 new ordinary shares in the capital of the Company pursuant to placement exercises that were completed on 17 Aug 2022 (the "August 2022 Placement Exercise") and 17 Nov 2022 (the "November 2022 Placement Exercise") respectively. The August 2022 Placement Exercise and November 22 Placement Exercise raised gross proceeds of approximately \$4 million and \$8 million respectively.

The newly issued shares rank pari passu in all respects with the previously issued shares.

The holders of ordinary shares are entitled to receive dividends as and when declared by the Company. All ordinary shares carry one vote per share without restriction.

The Company did not hold any treasury shares or convertibles as at 30 Nov 2022 and 31 May 2022.

The Company's subsidiaries do not hold any shares in the Company as at 30 Nov 2022 and 31 May 2022.

15 Subsequent event

- i) On 14 December 2022, the Company granted a total of 42,200,000 share options to certain eligible participants ("Grantees") under the Company's Employee Share Option Scheme ("ESOS") adopted by the shareholders of the Company on 30 September 2021. Subject to the acceptance by the Grantees, the Options will entitle the Grantees to subscribe for a total of 42,200,000 new shares of the Company at the exercise price of \$\$0.1022. 50% of the Options will vest after the first anniversary of the Date of Grant of the Options and up to 100% of the Options will vest after the second anniversary of the Date of Grant of the Options.
- ii) On 14 December 2022, the Company obtained shareholders' approval for the resolutions set out in the Notice of the Extraordinary General Meeting ("EGM") of the Company dated 29 November 2022, in relation to, *inter alia*, the proposed acquisition of the remaining 49.0% shareholding in the total ordinary share capital of International Biometrics Pte. Ltd. ("InterBIO"), being deemed as an interested person transaction under the Catalist Rules.
- iii) On 10 January 2023, the Company has completed the acquisition of the remaining 49.0% of the shareholding in the total ordinary share capital of InterBio and InterBio is now a wholly-owned subsidiary of the Company. As the base consideration and introducer fees payable for the acquisition, the Company has allotted and issued 365,365,000 base consideration shares and 21,921,900 introducer shares at an issue price of \$\$0.14 per such share. Resultingly, the total number of issued and paid-up share capital of the Company has increased from 953,703,716 Shares to 1,340,990,616 shares.



Other information Required by Listing Rule

Appendix 7C



Other information required by Listing Rule Appendix 7C

1 Review

The condensed interim statement of financial position of TOTM Technologies Limited and its subsidiaries as at 30 November 2022 and the related condensed interim consolidated statement of profit or loss and other comprehensive income, condensed interim statement of changes in equity and condensed interim consolidated statement of cash flows for the six months then ended and the notes have not been audited or reviewed.

2 A review of the performance of the Group

2.1 Review of the Group's Consolidated Statement of Profit or Loss and Other Comprehensive Income

Revenue

The Group's revenue increased by 112.0% from \$8.0 million for the half-year ended 30 November 2021 ("**1H2022**") to \$16.9 million for the half-year ended 30 November 2022 ("**1H2023**"). The revenue represents only the Biometrics business since the Group has disposed the entire Telecommunication business in financial year ended 31 May 2022. The revenue from Biometrics business was mainly derived from:

- (i) provision of technical support to Indonesia's Ministry of Home Affairs and maintenance of Indonesia's current biometric national identity system which contributed \$2.4 million; and
- (ii) two projects to supply biometric identification systems integrated with the National ID database, as well as supply biometric identification and surveillance systems to one of the law enforcement agencies in Indonesia, which contributed \$14.3 million.

Subcontractor costs and direct costs

These represent the costs related to our projects and these costs increased by approximately \$7.5 million or 137.8% from \$5.4 million in 1H2022 to \$12.9 million in 1H2023. The increase is in-line with the increase in revenue and also mainly a result of cost incurred with respect to the projects undertaken for the Indonesian law enforcement agency. Such costs include licenses, software and hardware costs.

Employee benefits expenses – Project / Admin

These represent the total staff costs incurred during the period. Employee benefit expenses for project staff increased by \$0.5 million to approximately \$0.5 million in 1H2023 from \$0.1 million in 1H2022, which is in line with the increase in operating activities as mentioned above. Employee benefit expenses for administrative staff increased slightly by \$0.1 million or 7.6% to \$1.9 million in 1H2023 from \$1.8 million in 1H2022, no significant changes in the administrative staff strength.

Depreciation and amortisation expenses

There were no significant changes to depreciation and amortisation expenses in absolute terms as there was no major capital expenditure incurred during the period. The increase was due mainly to the amortisation of intangibles of GenesisPro Pte Ltd, which was acquired in end September 2021

Legal and professional fees expenses

The decrease in legal and professional fees paid to professional firms incurred in respect of the various corporate by approximately \$0.7 million or 24.7% to \$2.1 million in 1H2023 from \$2.7 million in 1H2022, was mainly due to more corporate exercises being carried out by the Company during 1H2022 as compared to 1H2023.



Other information required by Listing Rule Appendix 7C

2 A review of the performance of the Group (Continued)

2.1 Review of the Group's Consolidated Statement of Profit or Loss and Other Comprehensive Income (Continued)

Other expenses

Other expenses increased by \$0.9 million to approximately \$1.5 million for in 1H2023 as compared to \$0.7 million in 1H2022. This was mainly due to the increase in marketing expenses, traveling and accommodation expenses, and office expenses as business activity picked up in 1H2023.

Finance costs

Finance costs comprise mainly of the interest component on the adoption of SFRS(I) 16 Leases throughout the Group and the increase related mainly to the office space in Central Business District area.

Taxation

Income tax credit comprised mainly from current taxation of \$0.1 million, and deferred taxation reversal/credit of \$0.4 million in FY2023.

2.2 Review of the Group's Statement of Consolidated Financial Position

Non-current assets

The decrease in non-current assets by approximately 4.0% or \$2.6 million to \$61.8 million as at 30 November 2022 from \$64.4 million as at 31 May 2022 was mainly due to the amortisation and depreciation charges, and no major capital expenditure incurred during the 1H2023.

Current assets

Current assets increased by approximately 182.3% or \$20.7 million to \$32.1 million as at 30 November 2022 from \$11.4 million as at 31 May 2022.

Trade and other receivables increased to \$15.6 million from \$3.9 million due to the two projects performed for the Indonesian law enforcement agency which was completed towards end of 1H2023.

Cash and bank balances increased to \$15.1 million as at 30 November 2022 from \$4.9 million as at 31 May 2022 due to proceeds from the August 2022 Placement Exercise and November 2022 Placement Exercise.



Other information required by Listing Rule Appendix 7C

2 A review of the performance of the Group (Continued)

2.2 Review of the Group's Statement of Consolidated Financial Position (Continued)

Non-current liabilities

Non-current liabilities decreased by approximately \$0.8 million to \$4.5 million as at 30 Nov 2022 from \$5.3 million as at 31 May 2022, mainly due to the repayment of lease liabilities and reversal of deferred tax liabilities during 1H2023.

Current liabilities

Current liabilities increased by approximately 583.9% or \$12.2 million to \$14.2 million as at 30 November 2022 from \$2.1 million as at 31 May 2022. This was mainly due to professional fees payable in respect of the various corporate exercises carried out by the Company during 1H2023 as well as the trade payables for the two projects performed for the Indonesian law enforcement agencies which was completed towards the end of the financial period.

Equity attributable to owners of the Company

Increase in total equity was mainly due to an issuance of new ordinary shares which resulted in an increase in the share capital, partially offset by an increase in accumulated losses.

2.3 Review of the Group's Consolidated Statement of Cash Flows

In 1H2023, net cash flows used in operating activities amounted to approximately \$0.8 million. This included operating cash outflows before changes in working capital of \$2.3 million, an increase in trade and other receivables of \$11.7 million, offset by increase in trade and other payables of \$12.1 million.

Net cash flows used in investing activities of \$0.3 million comprises \$0.1 million pertained to purchase of property, plant and equipment and \$0.2 million on purchases of intangible assets, which relates to development cost of an application by a third party developer.

Net cash flows generated from financing activities amounted to approximately \$11.3 million, mainly due to net proceeds from issuance of new ordinary shares from subscription exercises amounting to \$12.2 million.

As a result of the above, there was a net increase of approximately \$10.2 million in cash and cash equivalents during the period.

As at 30 November 2022, the Group's cash and cash equivalents amounted to approximately \$15.1 million.

3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable. No forecast or prospect statement has been previously disclosed to shareholders.



Other information required by Listing Rule Appendix 7C

4 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

According to MarketsandMarkets, the global digital identity solutions market size is projected to grow from US\$27.9 billion in 2022 to US\$70.7 billion by 2027, recording a CAGR of 20.4% from 2022 to 2027¹. PwC Strategy& opined that the doubledigit growth will principally result from a greater focus on customer experience, the escalating risk of cyber fraud and identity theft, and the increasing use of biometrics². The swift adoption of e-government platforms shows the potential of the digital ID market and creates an ideal foundation for considerable expansion for online services in the private sector as well.

Leveraging the Group's expertise and track record in hyper-scale end-to-end digital identity solutions, the Group is currently in discussions with potential parties to provide turnkey solutions for national identity, digital identity as well as digital onboarding projects in Asia Pacific and Middle East and Africa (MENA).

The Group will continue to explore new investment targets or partners across the digital identity space and biometrics industry value chain in order to build new identity management capabilities, products and markets.

¹ Digital Identity Solutions Market by Component (Solutions and Services), Solution Type (Biometrics and Non-Biometrics), Authentication Type, Deployment Mode, Organization Size, Vertical, and Region - Global Forecast to 2027, <u>https://www.marketsandmarkets.com/Market-Reports/digital-identity-solutions-market-247527694.html</u>

² Digital Identity: Opportunities and challenges, <u>https://www.strategyand.pwc.com/ip/ja/publications/digital-identity-e.pdf</u>



Other information required by Listing Rule Appendix 7C

5 Dividend

(a) Current Financial Period Reported on: Any dividend declared for the current financial period reported on?

No dividend was declared or recommended.

(b) Corresponding Period of the Immediately Preceding Financial Year: Any dividend declared for the corresponding period of the immediately preceding financial year?

No dividend was declared or recommended in the previous corresponding period.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Not applicable.

(d) Date payable

Not applicable.

(e) Books closure date.

Not applicable.

6 If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend was declared or recommended in respect of 1H2023 due to the Group's loss-making position.



Other information required by Listing Rule Appendix 7C

7 If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate. The aggregate value of all interested person transactions during the financial period under review was less than \$100,000, other than the following:

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than \$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than \$100,000)
PT International Biometrics Indonesia	Subsidiary	\$606,000 ⁽¹⁾	-

Note (1): In the period under review, the Group entered into transactions with PT International Biometrics Indonesia ("PT IBI") and wholly owned subsidiary, TOTM Tech India Private Limited has provided design and support work with respect to biometrics services on behalf of and as instructed by PT IBI amounting to \$606,000. Mr Pierre Prunier, Chief Executive Officer and Executive Director of the Group, as at 30 November 2022 holds 17.15% in InterBIO, the parent company of PT IBI, by virtue of his shareholdings in No Ka Oi Private Limited and Prundjaya Capital Pte. Ltd. Hence, it is disclosed on a prudent basis for transactions between the Group and PT IBI to be interested person transactions. The Group had, on 10 January 2023 announced the completion of acquisition of the remaining 49.0% of InterBIO. Following completion of the remaining 49.0% of InterBIO. InterBIO will be a wholly-owned subsidiary of the Company and Mr Pierre Prunier has ceased to have any interest in InterBIO.

8 Negative confirmation pursuant to Rule 705(5)

The Board of Directors hereby confirms that, to the best of their knowledge, nothing has come to their attention which may render the unaudited financial statements for the half year ended 30 November 2022 to be false or misleading in any material aspect.

9 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H under Rule 720(1))

The Company hereby confirms that it has procured undertakings from all its Directors and the relevant executive officers in the format as set out in Appendix 7H in accordance with Rule 720(1) of the Catalist Rules.

10 Disclosures pursuant to Rule 706A of the Catalist Rules

Please refer to the Company's announcement dated 17 October 2022 and circular dated 29 November 2022, in relation to the proposed acquisition of the remaining 49.0% shareholding in the total ordinary share capital of InterBIO for an aggregate purchase consideration of up to US\$46,060,000 (equivalent to S\$65,865,800) to be satisfied via the allotment and issue of up to 470,470,000 new ordinary shares in the capital of the Company (the "**Shares**") at the fixed issue price of S\$0.14 per such Share (the "**Proposed Acquisition**"). Shareholders' approval on the Proposed Acquisition has been obtained pursuant to the EGM held on 14 December 2022. The Proposed Acquisition has been completed on 10 January 2023.



Other information required by Listing Rule Appendix 7C

11. Update on use of proceeds from placement

The Company refers to the announcement released on 30 June 2022 and 20 December 2022 in relation to the use of net proceeds from the following subscription and placement exercises:-

- a) share subscription of 76,000,000 Shares that was announced on 29 September 2020 and completed on 16 October 2020 (the "**October 2020 Subscription Exercise**");
- b) share subscription of 195,000,000 Shares that was announced on 11 May 2021 and completed on 25 June 2021 (the "June 2021 Placement Exercise");
- share subscription of 33,400,000 Shares that was announced on 5 August 2022 and completed on 17
 August 2022 (the "August 2022 Placement Exercise").
- d) share subscription of 71,000,000 Shares that was announced on 28 October 2022 and completed on 17 November 2022 (the "**November 2022 Placement Exercise**").

As at the date of this announcement, the remaining net proceeds and the intended use of net proceeds from the fund raising exercises are as follows:

S\$'000	October 2020 Subscription Exercise	June 2021 Placement Exercise ⁽¹⁾	August 2022 Placement Exercise	November 2022 Placement Exercise
Net proceeds utilised for working capital since 30 June 2022 to the date of this announcement	-	(3,184)	(1,588)	-
Net proceeds remaining (in relation to prior fund raising exercises) for working capital as at the date of this announcement	-	-	2,270	3,944
Net proceeds utilised for new business opportunities since 30 June 2022 to the date of this announcement	(477)	-	-	-
Net proceeds remaining (in relation to prior fund raising exercises) for new business opportunities as at the date of this announcement	33 ⁽²⁾	-	-	3,944



Other information required by Listing Rule Appendix 7C

11. Update on use of proceeds from placement (Continued)

Notes:

- (1) Please refer to the announcement dated 30 June 2022 by the Company for more details on the re-allocated proceeds from the June 2021 Placement Exercise for working capital.
- (2) Please refer to the announcement dated 20 December 2022 by the Company. An investment amount of S\$510,000 from the October 2020 Subscription Exercise was initially set aside for a joint venture with InterBio as mentioned in the 2 December 2020 announcement by the Company. Subsequent to the completion of the Company's acquisition of the remaining 49.0% of InterBio ("Proposed Acquisition") as announced on 10 January 2023, InterBIO will be a wholly-owned subsidiary of the Company. Hence, the S\$510,000 set aside for the joint venture with InterBIO have instead been used to fund the related professional fees for the Proposed Acquisition.

A breakdown of the net proceeds from the June 2021 Placement Exercise and August 2022 Placement Exercise that were utilised since 30 June 2022 for working capital is as follows:

Summary of expenses:	Working capital (S\$'000)
Listing fees	40
Staff costs and director fees	1,377
Finance cost or bank charges	2
Professional fees	1,427
Administrative expenses	1,666
Purchases from supplier	260
Total	4,772

CONFIRMATION BY THE BOARD

On behalf of the Board of Directors of the Company, we the undersigned, hereby confirm to the best of our knowledge that nothing come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the six months ended 30 November 2022 to be false or misleading in any material aspect.

On behalf of the Board of Directors

Prunier Pierre Olivier Marc Yves Chief Executive Officer and Executive Director Gordon Tan Chee Bun Executive Director

Singapore 14 January 2023